149
Views
14
CrossRef citations to date
0
Altmetric
Review

Yttrium 90 ibritumomab tiuxetan in lymphoma

, , , , &
Pages 967-977 | Accepted 11 Jan 2006, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Pier Paolo Piccaluga, Maria Rosaria Sapienza, Claudio Agostinelli, Carlo Sagramoso, Claudia Mannu, Elena Sabattini, Pier Luigi Zinzani & Stefano A Pileri. (2009) Biology and treatment of follicular lymphoma. Expert Review of Hematology 2:5, pages 533-547.
Read now
Sofiane Maza, Sylke Gellrich, Chalid Assaf, Marc Beyer, Laura Spilker, Helmut Orawa, Dieter L. Munz, Wolfram Sterry & Matthias Steinhoff. (2008) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study. Leukemia & Lymphoma 49:9, pages 1702-1709.
Read now
Alexandra Stefanovic, Daniel Morgensztern, Thomas Fong & Izidore S. Lossos$suffix/text()$suffix/text(). (2008) Pulmonary marginal zone lymphoma: A single centre experience and review of the SEER database. Leukemia & Lymphoma 49:7, pages 1311-1320.
Read now
Jatin Shah, Wenquan Wang, V. Douglas Harrough, Wayne Saville, Ruby Meredith, Sui Shen, John Mueh, John Lister, Sri Jasthy, Gregory Maggass, Charles McKay, Richard Krumdieck, Morgan Tharp, Christine Winter, Stephanie Gregory, William Buchholz, Sanjay Awasthi, Samuel Jacobs, Harold Chung, James Egner, Albert F. Lobuglio & Andres Forero. (2007) Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leukemia & Lymphoma 48:9, pages 1736-1744.
Read now

Articles from other publishers (10)

A. D. Shirin, O. Yu. Baranova & V. V. Reshetnikova. (2023) Immunological aspects of hematopoietic stem cell transplantation for hematologic malignancies and some immunological peculiarities of cancer radioimmunotherapy. Russian Journal of Biotherapy 22:2, pages 10-19.
Crossref
Umair Khalid, Chris Vi, Justin Henri, Joanna Macdonald, Peter Eu, Giovanni Mandarano & Sarah Shigdar. (2018) Radiolabelled Aptamers for Theranostic Treatment of Cancer. Pharmaceuticals 12:1, pages 2.
Crossref
F. F. Knapp & Ashutosh DashF. F. Knapp & Ashutosh Dash. 2016. Radiopharmaceuticals for Therapy. Radiopharmaceuticals for Therapy 71 113 .
Thomas E. Witzig. 2010. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer 169 218 .
Umberto Vitolo, Giovanni Barosi, Stefano Fanti, Alessandro M. Gianni, Maurizio Martelli, Mario Petrini, Pier Luigi Zinzani & Sante Tura. (2010) Consensus conference on the use of 90‐yttrium‐ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. American Journal of Hematology 85:2, pages 147-155.
Crossref
C. Triby, P. Carrier, F. Peyrade, N. Mounier, X. Fontana, J.-P. Chaborel, L. Tessonnier, D. Benisvy, M. Razzouk, F. Bussière & J. Darcourt. (2008) Quelques perspectives concernant le traitement des lymphomes par Zevalin® à partir de l’évaluation de l’expérience niçoise. Médecine Nucléaire 32:2, pages 85-95.
Crossref
Pier Luigi Zinzani, Francesco d’Amore, Emilio Bombardieri, Caroline Brammer, José Gómez Codina, Tim Illidge, Wojciech Jurczak, Werner Linkesch, Franck Morschhauser, Elisabeth Vandenberghe & Achiel Van Hoof. (2008) Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop. European Journal of Cancer 44:3, pages 366-373.
Crossref
C Gisselbrecht, W Bethge, R F Duarte, A M Gianni, B Glass, C Haioun, G Martinelli, A Nagler, R Pettengell, A Sureda, H Tilly & K Wilson. (2007) Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 40:11, pages 1007-1017.
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:1, pages 44-51.
Crossref
Christian Menzel & Stefan Dübel. 2007. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 1131 1147 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.